Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection.
Fontana RJ, Brown RS Jr, Moreno-Zamora A, Prieto M, Joshi S, Londoño MC, Herzer K, Chacko KR, Stauber RE, Knop V, Jafri SM, Castells L, Ferenci P, Torti C, Durand CM, Loiacono L, Lionetti R, Bahirwani R, Weiland O, Mubarak A, ElSharkawy AM, Stadler B, Montalbano M, Berg C, Pellicelli AM, Stenmark S, Vekeman F, Ionescu-Ittu R, Emond B, Reddy KR. Fontana RJ, et al. Among authors: knop v. Liver Transpl. 2016 Apr;22(4):446-58. doi: 10.1002/lt.24416. Liver Transpl. 2016. PMID: 26890629 Free article.
Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity but no clinical benefit if treatment is given late.
Pellicelli AM, Montalbano M, Lionetti R, Durand C, Ferenci P, D'Offizi G, Knop V, Telese A, Lenci I, Andreoli A, Zeuzem S, Angelico M. Pellicelli AM, et al. Among authors: knop v. Dig Liver Dis. 2014 Oct;46(10):923-7. doi: 10.1016/j.dld.2014.06.004. Epub 2014 Jul 3. Dig Liver Dis. 2014. PMID: 24997638 Clinical Trial.
Apolipoprotein E allele frequencies in chronic and self-limited hepatitis C suggest a protective effect of APOE4 in the course of hepatitis C virus infection.
Mueller T, Fischer J, Gessner R, Rosendahl J, Böhm S, van Bömmel F, Knop V, Sarrazin C, Witt H, Marques AM, Kovacs P, Schleinitz D, Stumvoll M, Blüher M, Bugert P, Schott E, Berg T. Mueller T, et al. Among authors: knop v. Liver Int. 2016 Sep;36(9):1267-74. doi: 10.1111/liv.13094. Epub 2016 Mar 23. Liver Int. 2016. PMID: 26880346
Non-invasive assessment of fibrosis regression and portal hypertension in patients with advanced chronic hepatitis C virus (HCV)-associated liver disease and sustained virologic response (SVR): 3 years follow-up of a prospective longitudinal study.
Knop V, Hoppe D, Vermehren J, Troetschler S, Herrmann E, Vermehren A, Friedrich-Rust M, Sarrazin C, Trebicka J, Zeuzem S, Welker MW. Knop V, et al. J Viral Hepat. 2021 Nov;28(11):1604-1613. doi: 10.1111/jvh.13587. Epub 2021 Oct 1. J Viral Hepat. 2021. PMID: 34342081
Estimation of liver fibrosis by noncommercial serum markers in comparison with transient elastography in patients with chronic hepatitis C virus infection receiving direct-acting antiviral treatment.
Knop V, Hofmann WP, Buggisch P, Klinker H, Mauss S, Günther R, Hinrichsen H, Hüppe D, Pfeiffer-Vornkahl H, Simon KG, Berg T, Manns MP, Friedrich-Rust M; German Hepatitis C-Registry. Knop V, et al. J Viral Hepat. 2019 Feb;26(2):224-230. doi: 10.1111/jvh.13021. Epub 2018 Nov 8. J Viral Hepat. 2019. PMID: 30315694
23 results